Mediwound

Yahoo Finance • yesterday

MediWound announces $30M registered direct offering

MediWound (MDWD) “announced that it has entered into a definitive securities purchase agreement led by a prominent U.S.-based mutual fund and other healthcare-focused investors for the sale and purchase of 1,734,105 ordinary shares of the... Full story

Yahoo Finance • 2 days ago

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

MediWoundAnnounces$30 Million Registered Direct Offering of Ordinary Shares YAVNE, Israel, September 29, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, t... Full story

Yahoo Finance • 6 days ago

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia

MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, Septem... Full story

Yahoo Finance • last month

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, ho... Full story

Yahoo Finance • 2 months ago

MediWound Ltd (NASDAQ:MDWD) Reports Mixed Q2 2025 Results with Revenue Growth but Wider-Than-Expected Losses

MediWound Ltd (NASDAQ:MDWD [https://www.chartmill.com/stock/quote/MDWD]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $5.7 million, a 43% s... Full story

Yahoo Finance • 2 months ago

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wo... Full story

Yahoo Finance • 2 months ago

MediWound to Report Second Quarter 2025 Financial Results

MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-gen... Full story

Yahoo Finance • 5 months ago

MediWound to Report First Quarter 2025 Financial Results

YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended... Full story

Yahoo Finance • 8 months ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in mid-2026 Strategic research collaborat... Full story

Yahoo Finance • 2 years ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study preparations progressing; Protocol submission to FDA expected in first quarter 2024 Ca... Full story

Yahoo Finance • 2 years ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik... Full story

Yahoo Finance • 2 years ago

MediWound to Report Third Quarter 2023 Financial Results

YAVNE, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the th... Full story

Yahoo Finance • 2 years ago

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

YAVNE, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the Committee for Medi... Full story

Yahoo Finance • 2 years ago

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Inn... Full story

Yahoo Finance • 2 years ago

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

YAVNE, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced collaboration with 3M Healt... Full story

Yahoo Finance • 2 years ago

MediWound Deploys NexoBrid® for Emergency Supply

YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to... Full story

Yahoo Finance • 2 years ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

YAVNE, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department o... Full story

Yahoo Finance • 2 years ago

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the u... Full story

Yahoo Finance • 2 years ago

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx® Phase III study protocol:FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders NexoBrid®U.S. commercial launch timing not anticipated toimpact revenues in 2023-202... Full story

Yahoo Finance • 2 years ago

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced a research collaboration ag... Full story